Newly uncovered enzyme mechanism could help target drug-resistant breast cancer

AI Summary

Researchers at Boston Children's Hospital and collaborators identified an enzyme mechanism that may drive treatment resistance in hormone receptor-positive breast cancer. The finding could support earlier detection of resistant cancer cells and guide development of targeted treatments.

One of the major challenges in treating the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance to treatment. In a recent study, Boston Children's Hospital researchers and colleagues discovered a new driver of resistance, pointing to a way to detect resistant cancer cells early and a possible way to target them.